| Major clinical outcomes in antiretroviral therapy (ART)–naive participants and in those not receiving ART at baseline in the SMART study Strategies for Management of Antiretroviral Therapy (SMART) Study Group The Journal of infectious diseases 197 (8), 1133-1144, 2008 | 576 | 2008 |
| Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management AMJ Wensing, DA Van De Vijver, G Angarano, B Åsjö, C Balotta, E Boeri, ... The Journal of infectious diseases 192 (6), 958-966, 2005 | 557 | 2005 |
| COMET: adaptive context-based modeling for ultrafast HIV-1 subtype identification D Struck, G Lawyer, AM Ternes, JC Schmit, DP Bercoff Nucleic acids research 42 (18), e144-e144, 2014 | 350 | 2014 |
| Transmission of drug-resistant HIV-1 is stabilizing in Europe J Vercauteren, AMJ Wensing, DAMC van de Vijver, J Albert, C Balotta, ... The Journal of infectious diseases 200 (10), 1503-1508, 2009 | 312 | 2009 |
| Inferior Clinical Outcome of the CD4+ Cell Count–Guided Antiretroviral Treatment Interruption Strategy in the SMART Study: Role of CD4+ Cell Counts and HIV … Strategies for Management of Antiretroviral Therapy (SMART) Study Group The Journal of infectious diseases 197 (8), 1145-1155, 2008 | 259 | 2008 |
| Updated European recommendations for the clinical use of HIV drug resistance testing AM Vandamme, A Sönnerborg, M Ait-Khaled, J Albert, B Asjo, L Bacheler, ... Antiviral therapy 9 (6), 829-848, 2004 | 193 | 2004 |
| European recommendations for the clinical use of HIV drug resistance testing: 2011 update AM Vandamme, RJ Camacho, F Ceccherini-Silberstein, A De Luca, ... Aids Rev 13 (2), 77-108, 2011 | 190 | 2011 |
| Transmission of HIV drug resistance and the predicted effect on current first-line regimens in Europe LM Hofstra, N Sauvageot, J Albert, I Alexiev, F Garcia, D Struck, ... Clinical infectious diseases 62 (5), 655-663, 2016 | 189 | 2016 |
| HIV-1 subtype distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics AB Abecasis, AMJ Wensing, D Paraskevis, J Vercauteren, K Theys, ... Retrovirology 10, 1-13, 2013 | 181 | 2013 |
| Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial SMART Study Group* Annals of internal medicine 149 (5), 289-299, 2008 | 167 | 2008 |
| European surveillance of ICU-acquired infections (HELICS-ICU): methods and main results C Suetens, I Morales, A Savey, M Palomar, M Hiesmayr, A Lepape, ... Journal of Hospital Infection 65 (2), 171-173, 2007 | 167 | 2007 |
| Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach D Paraskevis, O Pybus, G Magiorkinis, A Hatzakis, AMJ Wensing, ... Retrovirology 6, 1-11, 2009 | 155 | 2009 |
| Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain JC Schmit, J Cogniaux, P Hermans, C Van Vaeck, S Sprecher, ... Journal of Infectious Diseases 174 (5), 962-968, 1996 | 145 | 1996 |
| The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes DA van de Vijver, AMJ Wensing, G Angarano, B Åsjö, C Balotta, E Boeri, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 41 (3), 352-360, 2006 | 136 | 2006 |
| Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538) E De Clercq, AM Vandamme Aids 10 (9), 995-999, 1996 | 129 | 1996 |
| Quantification of HIV-1 RNA in plasma: comparable results with the NASBA HIV-1 RNA QT and the AMPLICOR HIV monitor test AM Vandamme, JC Schmit, S Van Dooren, K Van Laethem, E Gobbers, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 13 (2), 127-139, 1996 | 127 | 1996 |
| Simple DNA extraction method for dried blood spots and comparison of two PCR assays for diagnosis of vertical human immunodeficiency virus type 1 transmission in Rwanda A Fischer, C Lejczak, C Lambert, J Servais, N Makombe, J Rusine, ... Journal of clinical microbiology 42 (1), 16-20, 2004 | 116 | 2004 |
| Function, diversity and therapeutic potential of the N-terminal domain of human chemokine receptors M Szpakowska, V Fievez, K Arumugan, N Van Nuland, JC Schmit, ... Biochemical pharmacology 84 (10), 1366-1380, 2012 | 108 | 2012 |
| HIV-associated hematologic disorders are correlated with plasma viral load and improve under highly active antiretroviral therapy J Servais, D Nkoghe, JC Schmit, V Arendt, I Robert, T Staub, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 28 (3), 203-210, 2001 | 103 | 2001 |
| Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues K Van Vaerenbergh, K Van Laethem, J Albert, CAB Boucher, B Clotet, ... Antimicrobial agents and chemotherapy 44 (8), 2109-2117, 2000 | 103 | 2000 |
